FormulaFolio Investments’s TherapeuticsMD TXMD Stock Holding History

FormulaFolio Investments’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-426	Closed	-$26K	–	783
2020 Q4	$26K	Buy	+426	New	+$29.1K	﹤0.01%	662

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FormulaFolio Investments's TXMD Position: Q1 2021 in Review

FormulaFolio Investments sold out of TherapeuticsMD (TXMD) in Q1 2021, closing a stake of 426 shares — an estimated $26K sold.

FormulaFolio Investments first reported a position in TXMD in Q4 2020 and held it in 1 quarter. The position peaked at $26K in Q4 2020. 160 funds tracked by Wall St. Rank hold TXMD as of Q1 2021.

FormulaFolio Investments reported no remaining TherapeuticsMD position as of Q1 2021 after selling out during the quarter.
FormulaFolio Investments sold 426 TherapeuticsMD shares in Q1 2021, an estimated $26K.
FormulaFolio Investments first reported a position in TherapeuticsMD in Q4 2020 and held it in 1 quarter.
FormulaFolio Investments's TherapeuticsMD position peaked at $26K in Q4 2020.
160 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2021.

Based on FormulaFolio Investments's 13F filing for Q1 2021, filed 28 May 2021.